

To Whom It May Concern

Date: July 3, 2026

Company Name: StemCell Institute Inc.

Representative: President Takafumi Shimizu

Company Name: NeuroTech Medical Co., Ltd.

Representative: President Nagatoshi Kihoin

StemCell Institute and NeuroTech Medical Begin Collaboration Toward the Use of Umbilical Cord-Derived Stem Cell Culture Supernatant “Family Supernatant” in the Field of Neuroregeneration

StemCell Institute Inc. (Head Office: Minato-ku, Tokyo; President: Takafumi Shimizu) and NeuroTech Medical Co., Ltd. (Head Office: Joto-ku, Osaka; President: Nagatoshi Kihoin) are pleased to announce that, effective July 3, 2026, the two companies have begun a collaboration toward the use of the umbilical cord-derived stem cell culture supernatant “Family Supernatant” in the field of neuroregeneration.


Through this collaboration, StemCell Institute, a perinatal tissue-derived cell bank centered on umbilical cord blood and umbilical cord tissue with a 99% share of the private cord blood banking market in Japan, and NeuroTech Medical, which provides “ReNeuro,” a medical service that combines its patented “Targeted Neuroregenerative Medicine” technology with its proprietary “Targeted Rehabilitation” approach, will build a framework for providing new medical services by leveraging the expertise of both companies.

Overview of the Collaboration

- Based on the instructions of physicians at NeuroTech Medical’s affiliated clinics, StemCell Institute will be entrusted with the manufacture of the stem cell culture supernatant “Family Supernatant” from umbilical cord-derived stem cells stored at StemCell Institute.
- NeuroTech Medical provides “ReNeuro,” which combines its patented “Targeted Neuroregenerative Medicine” technology with its proprietary “Targeted Rehabilitation” approach. Through this collaboration, physicians at NeuroTech Medical’s affiliated clinics will consider the use of Family Supernatant as one of the treatment options in privately funded medical care in the field of neuroregeneration, depending on each patient’s condition and other relevant factors.



▲ Family Supernatant Manufacturing Process



▲ Stroke and spinal cord injury clinic, Ginza

About StemCell Institute’s “Family Supernatant”

“Family Supernatant” is a service that manufactures stem cell culture supernatant using umbilical cord-derived stem cells from a child whose cells are stored at StemCell Institute. This service is currently provided only by StemCell Institute in Japan. “ファミリー上清®” is a registered trademark of StemCell Institute in Japan, and “Family Supernatant” is used as its English rendering.

About NeuroTech Medical’s “ReNeuro”

“ReNeuro,” provided by NeuroTech Medical, is a medical service in the field of neuroregeneration that combines NeuroTech Medical’s proprietary neuroregenerative technology and rehabilitation methods, and is provided based on physicians’ responsibility and judgment. Through this collaboration, physicians at NeuroTech Medical’s affiliated clinics will consider the use of Family Supernatant as one of the treatment options based on their medical judgment.

The impact of this matter on StemCell Institute’s financial results is expected to be minimal.

■ StemCell Institute Inc.

Under the corporate slogan “New medical options for new life,” the StemCell Institute Group operates a cell banking business for perinatal tissue-derived cells, such as umbilical cord tissue and umbilical cord blood, for the purpose of regenerative medicine and cell therapy, utilizing its strong network with obstetric medical institutions.

In addition, by leveraging this business foundation, the Group is working to develop new treatment methods in the fields of regenerative medicine and cell therapy, as well as to pursue business development and investment in related fields. Through these initiatives, the Group aims to expand its business domains, diversify revenue opportunities, and contribute to society through global and sustainable growth.

Established: August 5, 1999 (Listed on TSE Growth: 7096)

Capital: JPY 704.8 million

President: Takafumi Shimizu

Head Office: 2F Tokyu Toranomon Building, 1-21-19 Toranomon, Minato-ku, Tokyo 105-0001

TEL / Website: +81-3-6811-3230 / <https://www.stemcell.co.jp/corporate/>

Group Companies: STEMCELL INNOVATIONS PTE. LTD. (Singapore), Milcare Co., Ltd.

■ NeuroTech Medical Co., Ltd.

NeuroTech Medical Co., Ltd. is a Japan-based medical technology company with the mission of “making recovery from neurological disorders a matter of course.” Through ReNeuro, which combines its patented “Targeted Neuroregenerative Medicine” technology designed to enhance the recovery potential of targeted neural circuits with its proprietary “Targeted Rehabilitation” approach, NeuroTech Medical aims to improve functional recovery and quality of life for patients with stroke and spinal cord injury.

Going forward, NeuroTech Medical will seek to further enhance its Targeted Neuroregenerative Medicine technology by utilizing the KENSAI cell donation system and stored cellular resources, while contributing to society through the provision of a practical regenerative medicine and rehabilitation platform.

Established: December 27, 2019

Capital: JPY 349,844,000

President: Nagatoshi Kihoin

Head Office: Murakami Jitsugyo Building 216, 1-13-13 Chuo, Joto-ku, Osaka 536-0005, Japan

TEL / Website: +81-6-7777-4685 / <https://neurotech.jp/>

Business Activities: Research, development, and practical application of *ReNeuro*, integrating Targeted Neural Regeneration Therapy and Targeted Rehabilitation for stroke and spinal cord injury patients.